NCT06213012 Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury
| NCT ID | NCT06213012 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Methodist Hospital Research Institute |
| Condition | Spinal Cord Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-12-06 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-12-06 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It has been demonstrated that the human lumbosacral spinal cord can be neuromodulated with epidural (ESS) and transcutaneous (TSS) spinal cord stimulation to enable recovery of standing and volitional control of the lower limbs after complete motor paralysis due to spinal cord injury (SCI). The work proposed herein will examine and identify distinct electrophysiological mechanisms underlying transcutaneous spinal stimulation (TSS) and epidural spinal stimulation (ESS) to define how these approaches determine the ability to maintain self-assisted standing after SCI.
Eligibility Criteria
Inclusion criteria 1. All participants must be able to provide a provision of a signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 22-75 years old. 4. Documentation from the participant's primary treating physician confirming a stable medical condition. 5. Inability to maintain standing independently without external support due to SCI AIS A-C. 6. Ability to tolerate at least 15 minutes in an upright (supported) position. 7. Able to self-transfer from the wheelchair and demonstrate active range of motion of bilateral upper extremities in gravity dependent plane. 8. Able to passively range bilateral lower extremities within normal mobility parameters including: 1. greater than 90 degrees of hip flexion and 165 degrees of hip extension; 2. greater than 90 degrees of knee flexion and reach neutral knee extension of 180 degrees; 3. neutral ankle position reaching a minimum of 90 degrees of dorsiflexion. 9. Participants should be on a stable intrathecal baclofen or oral anti-spasticity regimen/dose for the period of the study unless advised otherwise by their physician. 10. 1 to 30 years post spinal cord injury. 11. Non-progressive spinal cord injury. 12. Neurological level of injury below C4 and above T12 (excluding conus injury and/or indications of lower motor neuron injury). 13. Eligible for fMRI per safety questionnaire. 14. Women of childbearing potential must agree to the use of an effective means of avoiding pregnancy for the duration of the study. 15. Able to commit to the full study. Exclusion Criteria: 1. Ability to maintain standing independently without external support. 2. Currently involved in another rehabilitation training of the lower extremities. 3. Active pressure sores, unhealed bone fractures, peripheral neuropathies, or painful musculoskeletal dysfunction (including but not limited to contractures in the upper and lower extremities). 4. Any ongoing medical condition which would preclude participant from regular physical activity (including but not limited to: cardiopulmonary disease, uncontrollable autonomic dysreflexia or orthostatic hypotension, active urinary tract infections, pregnant or nursing). 5. Intrathecal baclofen pump therapy for spasticity not compatible with 3T MRI. 6. Must not have received Botox injections to primary lower extremity and trunk musculature within the past 3 months, resulting in absence of muscle tone and precluding response to electrical stimulation therapy. 7. Current or history of neuromuscular conditions (including but not limited to: unhealed ligament of muscular tears in the upper or lower extremities, pain in weight bearing positions for upper and lower extremities). 8. Clinically significant depression, psychiatric disorders, or ongoing drug abuse, including heavy alcohol use. 9. Any reason the PI or treating physician may deem as harmful to the participant to enroll or continue in the study. 10. Body Mass Index (BMI) over 30. 11. Pregnancy. 12. Use a ventilator or diaphragmatic pacer. 13. Participants with the following conditions will be excluded from TMS, but may take part in the overall study: * Personal or first-degree family history of seizures or epilepsy. * Metal in the head, except mouth implants. * History of suicide attempts. * History of intracranial lesions, increased intracranial pressure, or stroke. * Current use of tricyclic anti-depressants, selective serotonin reuptake inhibitors (SSRIs), serotonin nor-epinephrine reuptake inhibitors (SNRIs), buproprion (Wellbutrin), or tramadol.
Contact & Investigator
Dimitry Sayenko, MD, PhD
PRINCIPAL INVESTIGATOR
The Methodist Hospital Research Institute
Frequently Asked Questions
Who can join the NCT06213012 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 75 Years, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06213012 currently recruiting?
Yes, NCT06213012 is actively recruiting participants. Contact the research team at jtdinh@houstonmethodist.org for enrollment information.
Where is the NCT06213012 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06213012 clinical trial?
NCT06213012 is sponsored by The Methodist Hospital Research Institute. The principal investigator is Dimitry Sayenko, MD, PhD at The Methodist Hospital Research Institute. The trial plans to enroll 60 participants.